Korea approves first anti-COVID-19 monoclonal antibody treatment 08 February 2021 | News CT-P59 is approved for the treatment of patients aged 60 years and over, or with at least one underlying medical condition, with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID- 19
Photo Credit: Freepik
Celltrion Group has announced that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted conditional marketing authorization (MA) for the emergency use of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment candidate. Conditional Marketing Authorization allows emergency use of CT-P59 in adult patients aged 60 years and over, or with at least one underlying medical condition (cardiovascular, chronic respiratory disease, diabetes, elevated blood pressure) mild symptoms of COVID-19, and in adult patients with moderate symptoms of COVID-19.